Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Effect of bardoxolone methyl on the urine albumin-to-creatinine ratio in patients with type 2 diabetes and stage 4 chronic kidney disease

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Improvements in albuminuria and chronic kidney disease progression with the appetite suppressant lorcaserin

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Challenges and opportunities for nephrology in Western Europe

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Arterial oxygen content regulates plasma erythropoietin independent of arterial oxygen tension: a blinded crossover study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Progression of diabetic kidney disease and trajectory of kidney function decline in Chinese patients with Type 2 diabetes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Peter Rossing
  • Geoffrey A Block
  • Melanie P Chin
  • Angie Goldsberry
  • Hiddo J L Heerspink
  • Peter A McCullough
  • Colin J Meyer
  • David Packham
  • Pablo E Pergola
  • Bruce Spinowitz
  • Stuart M Sprague
  • David G Warnock
  • Glenn M Chertow
Vis graf over relationer

Bardoxolone methyl attenuates inflammation by inducing nuclear factor erythroid-derived 2-related factor 2 and suppressing nuclear factor κB. The Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes (BEACON) trial was a phase 3 placebo-controlled, randomized, double-blind, parallel-group, international, multicenter trial in 2185 patients with type 2 diabetes mellitus and stage 4 chronic kidney disease. BEACON was terminated because of safety concerns, largely related to a significant increase in early heart failure events in patients randomized to bardoxolone methyl. Bardoxolone methyl resulted in increased estimated glomerular filtration rate (eGFR) and urine albumin-to-creatinine ratio. Herein, we present post hoc analyses characterizing the relation between the urine albumin-to-creatinine ratio and eGFR. The urine albumin-to-creatinine ratio and eGFR were assessed every four weeks through Week 12, followed by assessments every eight weeks thereafter, and 4 weeks after the last dose of bardoxolone methyl was administered. The initial increases in urine albumin-to-creatinine ratio observed in patients randomized to bardoxolone methyl were attenuated after six months. Multivariable regression analysis identified baseline eGFR and eGFR over time as the dominant factors associated with change in the urine albumin-to-creatinine ratio. Relative to placebo, bardoxolone methyl resulted in a significant decrease in albuminuria when indexed to eGFR (least-squared means: −0.035 [95% confidence interval −0.031 to −0.039]). Thus, among patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl, changes in albuminuria are directly related to changes in eGFR, challenging the conventional construct that increases in albuminuria universally reflect kidney injury and denote harm.

OriginalsprogEngelsk
TidsskriftKidney International
Vol/bind96
Udgave nummer4
Sider (fra-til)1030-1036
Antal sider7
ISSN0085-2538
DOI
StatusUdgivet - 1 okt. 2019

Bibliografisk note

Copyright © 2019 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.

ID: 57722506